1.13
전일 마감가:
$1.12
열려 있는:
$1.14
하루 거래량:
30,310
Relative Volume:
0.47
시가총액:
$22.90M
수익:
-
순이익/손실:
$-22.29M
주가수익비율:
-0.9576
EPS:
-1.18
순현금흐름:
$-17.12M
1주 성능:
-3.37%
1개월 성능:
+22.85%
6개월 성능:
-1.72%
1년 성능:
-16.67%
엔라이벡스 Stock (ENLV) Company Profile
ENLV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ENLV
Enlivex Therapeutics Ltd
|
1.13 | 22.90M | 0 | -22.29M | -17.12M | -1.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
451.48 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
536.76 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
552.05 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.50 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Sepsis Market Growth to Accelerate in Forecast Period - openPR.com
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle
Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel
Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus
Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus
Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times
Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan
Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal
Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times
Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud
Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times
ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus
Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com
Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus
Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView
Game-Changing Cell Therapy Helps Patients Avoid Knee Replacement: Clinical Trial Results Revealed - Stock Titan
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo
Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at D. Boral Capital - Defense World
Enlivex (ENLV) Completes Patient Enrollment for Phase II Allocetra Trial | ENLV Stock News - GuruFocus
Enlivex Completes Phase II Enrollment for Osteoarthritis Trial - TipRanks
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - The Manila Times
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis | ENLV Stock News - GuruFocus
Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra - Stock Titan
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment - TipRanks
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need - Stock Titan
Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks
HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):